Vulvodynia Treatment Market: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)
There is an increasing tendency of women who have observed chronic vulvar pain once in a lifetime. If the pain is persistent for more than three months and has no apparent cause, it is called vulvodynia. It is estimated that 16% of women in the U.S. will have Vulvodynia at some point in their lives. According to the National Center for Biotechnology Information, U.S. National Library of Medicine, 17.9% of women reported symptoms suggestive of past Vulvodynia in 2013. Based on an analysis, 101,007 women in the 4-county area are estimated to have vulvar pain consistent with Vulvodynia, with another 218,219 having a history of such pain that has since resolved. As a result of these factors, the demand for the drugs is constantly rising. The drug type and its use is measured by the level of pain that is caused of vulvodynia. Although it is a chronic disease, at times even the minutest of pain can cause depression and anxiety among women.
Anticonvulsant to be the most used drug
Anticonvulsant is a type of medication that is used for controlling seizures or stop an ongoing series of seizures (convulsions). In Vulvodynia treatment, anticonvulsant is the most prescribed drug. Gabapentin is most reliable anticonvulsant drug available in vulvodynia treatment. Gabapentin is a drug which has long been recognized in chronic pain management as an effective way of curing pain. It contains tablets taken by mouth and works well for pain related to the nerve. The tablets are prescribed for a number of conditions impacting the central nervous system and they influence pain at the level of the spinal cord. Pregabalin is another anticonvulsant drug. It is very similar to gabapentin; however, it is reported to have fewer side effects and is possibly more operative. Tricyclic antidepressant to rise in consumption
Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. These can be prescribed by your doctor in doses lower than those used to treat depression. The drugs are used because they alter the way in which the nerve fibres transmit the sensation of pain, not because the doctor thinks it's all in your mind. It is often necessary to continue with treatment for 3-6 months. Examples of tablets include amitriptyline, nortriptyline and dothiepin. Other antidepressants namely venlafaxine can also be tried. As the treatment of vulvodynia is mainly centred at placebo, antidepressants are the first of form of medical treatments given to a patient in case of minor pains.
Use of local anaesthetic to rise globally
Local anaesthetics are generally applied externally to the skin. This medication originates in a form of gel or cream. They may be used before sexual intercourse to provide short-term pain relief, or they can be used for extended periods. Local anaesthetic is used topically to introitus, which decrease hypersensitivity. This medication need to apply before intercourse or nightly on a cotton ball in the introitus. Lidocaine gel or cream is considered to be the best local anaesthetic cream or gel for vulvodynia.
- 1. Executive Summary
- 1.1. Market Overview
- 1.2. Market Analysis
- 1.3. FMI Analysis and Recommendations
- 1.4. Wheel of Fortune
- 2. Market Introduction
- 2.1. Market Taxonomy
- 2.2. Market Definition
- 3. Vulvodynia Treatment Market View Point
- 3.1. Macro-Economic Factors
- 3.2. Opportunity Analysis
- 3.3. Occurrence of Vulvodynia
- 3.4. Regulatory Scenario
- 4. Vulvodynia Treatment Market Dynamics
- 4.1. Drivers
- 4.2. Restraints
- 4.3. Opportunities
- 4.4. Trends
- 5. North America Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 5.1. Introduction
- 5.2. Regional Market Dynamics
- 5.3. Historical Market Size (US$ Mn) By Country, 2013-2017
- 5.3.1. U.S.
- 5.3.2. Canada
- 5.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
- 5.4.1. U.S.
- 5.4.2. Canada
- 5.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 5.5.1. Anticonvulsant
- 5.5.2. Tricyclic Antidepressant
- 5.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 5.5.4. Hormone
- 5.5.5. Nerve Block
- 5.5.6. Local Anesthetic
- 5.5.7. Others
- 5.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 5.6.1. Anticonvulsant
- 5.6.2. Tricyclic Antidepressant
- 5.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 5.6.4. Hormone
- 5.6.5. Nerve Block
- 5.6.6. Local Anesthetic
- 5.6.7. Others
- 5.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 5.7.1. Oral
- 5.7.2. Topical
- 5.7.3. Injectable
- 5.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 5.8.1. Oral
- 5.8.2. Topical
- 5.8.3. Injectable
- 5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 5.9.1. Hospital Pharmacies
- 5.9.2. Retail Pharmacies
- 5.9.3. Drug Stores
- 5.9.4. Online Pharmacies
- 5.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 5.10.1. Hospital Pharmacies
- 5.10.2. Retail Pharmacies
- 5.10.3. Drug Stores
- 5.10.4. Online Pharmacies
- 5.11. Drivers and Restraints: Impact Analysis
- 5.12. Market Attractiveness Analysis
- 5.12.1. By Country
- 5.12.2. By Drug Class
- 5.12.3. By Mode Of Administration
- 5.12.4. By Distribution Channel
- 5.13. Key Representative Market Participants
- 5.14. Key Participants Market Presence (Intensity Map)
- 6. Latin America Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 6.1. Introduction
- 6.2. Regional Market Dynamics
- 6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
- 6.3.1. Brazil
- 6.3.2. Mexico
- 6.3.3. Rest of Latin America
- 6.4. Market Size (US$ Mn) Forecast By Country, 2018–2028
- 6.4.1. Brazil
- 6.4.2. Mexico
- 6.4.3. Rest of Latin America
- 6.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 6.5.1. Anticonvulsant
- 6.5.2. Tricyclic Antidepressant
- 6.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 6.5.4. Hormone
- 6.5.5. Nerve Block
- 6.5.6. Local Anesthetic
- 6.5.7. Others
- 6.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 6.6.1. Anticonvulsant
- 6.6.2. Tricyclic Antidepressant
- 6.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 6.6.4. Hormone
- 6.6.5. Nerve Block
- 6.6.6. Local Anesthetic
- 6.6.7. Others
- 6.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 6.7.1. Oral
- 6.7.2. Topical
- 6.7.3. Injectable
- 6.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 6.8.1. Oral
- 6.8.2. Topical
- 6.8.3. Injectable
- 6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 6.9.1. Hospital Pharmacies
- 6.9.2. Retail Pharmacies
- 6.9.3. Drug Stores
- 6.9.4. Online Pharmacies
- 6.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 6.10.1. Hospital Pharmacies
- 6.10.2. Retail Pharmacies
- 6.10.3. Drug Stores
- 6.10.4. Online Pharmacies
- 6.11. Drivers and Restraints: Impact Analysis
- 6.12. Market Attractiveness Analysis
- 6.12.1. By Country
- 6.12.2. By Drug Class
- 6.12.3. By Mode Of Administration
- 6.12.4. By Distribution Channel
- 6.13. Key Representative Market Participants
- 6.14. Key Participants Market Presence (Intensity Map)
- 7. Western Europe Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 7.1. Introduction
- 7.2. Regional Market Dynamics
- 7.3. Historical Market Size (US$ Mn) By Country, 2013-2017
- 7.3.1. Germany
- 7.3.2. United Kingdom
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Nordic Region
- 7.3.7. Rest of Western Europe
- 7.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
- 7.4.1. Germany
- 7.4.2. United Kingdom
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Nordic Region
- 7.4.7. Rest of Western Europe
- 7.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 7.5.1. Anticonvulsant
- 7.5.2. Tricyclic Antidepressant
- 7.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 7.5.4. Hormone
- 7.5.5. Nerve Block
- 7.5.6. Local Anesthetic
- 7.5.7. Others
- 7.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 7.6.1. Anticonvulsant
- 7.6.2. Tricyclic Antidepressant
- 7.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 7.6.4. Hormone
- 7.6.5. Nerve Block
- 7.6.6. Local Anesthetic
- 7.6.7. Others
- 7.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 7.7.1. Oral
- 7.7.2. Topical
- 7.7.3. Injectable
- 7.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 7.8.1. Oral
- 7.8.2. Topical
- 7.8.3. Injectable
- 7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 7.9.1. Hospital Pharmacies
- 7.9.2. Retail Pharmacies
- 7.9.3. Drug Stores
- 7.9.4. Online Pharmacies
- 7.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 7.10.1. Hospital Pharmacies
- 7.10.2. Retail Pharmacies
- 7.10.3. Drug Stores
- 7.10.4. Online Pharmacies
- 7.11. Drivers and Restraints: Impact Analysis
- 7.12. Market Attractiveness Analysis
- 7.12.1. By Country
- 7.12.2. By Drug Class
- 7.12.3. By Mode Of Administration
- 7.12.4. By Distribution Channel
- 7.13.Key Representative Market Participants
- 7.14.Key Participants Market Presence (Intensity Map)
- 8. Eastern Europe Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 8.1. Introduction
- 8.2. Regional Market Dynamics
- 8.3. Historical Market Size (US$ Mn) By Country, 2013-2017
- 8.3.1. Russia
- 8.3.2. Poland
- 8.3.3. Rest of Eastern Europe
- 8.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
- 8.4.1. Russia
- 8.4.2. Poland
- 8.4.3. Rest of Eastern Europe
- 8.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 8.5.1. Anticonvulsant
- 8.5.2. Tricyclic Antidepressant
- 8.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 8.5.4. Hormone
- 8.5.5. Nerve Block
- 8.5.6. Local Anesthetic
- 8.5.7. Others
- 8.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 8.6.1. Anticonvulsant
- 8.6.2. Tricyclic Antidepressant
- 8.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 8.6.4. Hormone
- 8.6.5. Nerve Block
- 8.6.6. Local Anesthetic
- 8.6.7. Others
- 8.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 8.7.1. Oral
- 8.7.2. Topical
- 8.7.3. Injectable
- 8.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 8.8.1. Oral
- 8.8.2. Topical
- 8.8.3. Injectable
- 8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 8.9.1. Hospital Pharmacies
- 8.9.2. Retail Pharmacies
- 8.9.3. Drug Stores
- 8.9.4. Online Pharmacies
- 8.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 8.10.1. Hospital Pharmacies
- 8.10.2. Retail Pharmacies
- 8.10.3. Drug Stores
- 8.10.4. Online Pharmacies
- 8.11. Drivers and Restraints: Impact Analysis
- 8.12. Market Attractiveness Analysis
- 8.12.1. By Country
- 8.12.2. By Drug Class
- 8.12.3. By Mode Of Administration
- 8.12.4. By Distribution Channel
- 8.13. Key Representative Market Participants
- 8.14. Key Participants Market Presence (Intensity Map)
- 9. Asia Pacific Excluding Japan Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 9.1. Introduction
- 9.2. Regional Market Dynamics
- 9.3. Historical Market Size (US$ Mn) By Country, 2013-2017
- 9.3.1. China
- 9.3.2. India
- 9.3.3. Australia and New Zealand
- 9.3.4. ASEAN
- 9.3.5. Rest of APEJ
- 9.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
- 9.4.1. China
- 9.4.2. India
- 9.4.3. Australia and New Zealand
- 9.4.4. ASEAN
- 9.4.5. Rest of APEJ
- 9.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 9.5.1. Anticonvulsant
- 9.5.2. Tricyclic Antidepressant
- 9.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 9.5.4. Hormone
- 9.5.5. Nerve Block
- 9.5.6. Local Anesthetic
- 9.5.7. Others
- 9.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 9.6.1. Local Anesthetic
- 9.6.2. Anticonvulsant
- 9.6.3. Tricyclic Antidepressant
- 9.6.4. Hormones
- 9.6.5. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 9.6.6. Nerve Block
- 9.6.7. Others
- 9.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 9.7.1. Oral
- 9.7.2. Topical
- 9.7.3. Injectable
- 9.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 9.8.1. Oral
- 9.8.2. Topical
- 9.8.3. Injectable
- 9.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 9.9.1. Hospital Pharmacies
- 9.9.2. Retail Pharmacies
- 9.9.3. Drug Stores
- 9.9.4. Online Pharmacies
- 9.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 9.10.1. Hospital Pharmacies
- 9.10.2. Retail Pharmacies
- 9.10.3. Drug Stores
- 9.10.4. Online Pharmacies
- 9.11. Drivers and Restraints: Impact Analysis
- 9.12. Market Attractiveness Analysis
- 9.12.1. By Country
- 9.12.2. By Drug Class
- 9.12.3. By Mode Of Administration
- 9.12.4. By Distribution Channel
- 9.13. Key Representative Market Participants
- 9.14. Key Participants Market Presence (Intensity Map)
- 10. Japan Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 10.1. Introduction
- 10.2. Regional Market Dynamics
- 10.3. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 10.3.1. Anticonvulsant
- 10.3.2. Tricyclic Antidepressant
- 10.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 10.3.4. Hormone
- 10.3.5. Nerve Block
- 10.3.6. Local Anesthetic
- 10.3.7. Others
- 10.4. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 10.4.1. Anticonvulsant
- 10.4.2. Tricyclic Antidepressant
- 10.4.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 10.4.4. Hormone
- 10.4.5. Nerve Block
- 10.4.6. Local Anesthetic
- 10.4.7. Others
- 10.5. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 10.5.1. Oral
- 10.5.2. Topical
- 10.5.3. Injectable
- 10.6. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 10.6.1. Oral
- 10.6.2. Topical
- 10.6.3. Injectable
- 10.7. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies
- 10.7.3. Drug Stores
- 10.7.4. Online Pharmacies
- 10.8. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 10.8.1. Hospital Pharmacies
- 10.8.2. Retail Pharmacies
- 10.8.3. Drug Stores
- 10.8.4. Online Pharmacies
- 10.9. Drivers and Restraints: Impact Analysis
- 10.10. Market Attractiveness Analysis
- 10.10.1. By Drug Class
- 10.10.2. By Mode Of Administration
- 10.10.3. By Distribution Channel
- 10.11. Key Representative Market Participants
- 10.12. Key Participants Market Presence (Intensity Map)
- 11. Middle East and Africa Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
- 11.1. Introduction
- 11.2. Regional Market Dynamics
- 11.2.1. Drivers
- 11.2.2. Restraints
- 11.2.3. Trends
- 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013–2017
- 11.3.1. GCC Countries
- 11.3.2. South Africa
- 11.3.3. Rest of MEA
- 11.4. Market Size (US$ Mn) Forecast By Country, , 2018–2028
- 11.4.1. GCC Countries
- 11.4.2. South Africa
- 11.4.3. Rest of MEA
- 11.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 11.5.1. Anticonvulsant
- 11.5.2. Tricyclic Antidepressant
- 11.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 11.5.4. Hormone
- 11.5.5. Nerve Block
- 11.5.6. Local Anesthetic
- 11.5.7. Others
- 11.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
- 11.6.1. Anticonvulsant
- 11.6.2. Tricyclic Antidepressant
- 11.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 11.6.4. Hormone
- 11.6.5. Nerve Block
- 11.6.6. Local Anesthetic
- 11.6.7. Others
- 11.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 11.7.1. Oral
- 11.7.2. Topical
- 11.7.3. Injectable
- 11.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 11.8.1. Oral
- 11.8.2. Topical
- 11.8.3. Injectable
- 11.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 11.9.1. Hospital Pharmacies
- 11.9.2. Retail Pharmacies
- 11.9.3. Drug Stores
- 11.9.4. Online Pharmacies
- 11.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 11.10.1. Hospital Pharmacies
- 11.10.2. Retail Pharmacies
- 11.10.3. Drug Stores
- 11.10.4. Online Pharmacies
- 11.11. Drivers and Restraints: Impact Analysis
- 11.12. Market Attractiveness Analysis
- 11.12.1. By Country
- 11.12.2. By Drug Class
- 11.12.3. By Mode Of Administration
- 11.12.4. By Distribution Channel
- 11.13. Key Representative Market Participants
- 11.14. Key Participants Market Presence (Intensity Map)
- 12. Forecast Factors: Relevance and Impact
- 13. Forecast Assumptions
- 14. Competition Landscape
- 14.1. Competition Dashboard
- 14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
- 14.2.1. GlaxoSmithKline plc.
- 14.2.2. AstraZeneca Plc.
- 14.2.3. Eli Lilly and Company
- 14.2.4. Merck & Co., Inc.
- 14.2.5. Pfizer Inc.
- 14.2.6. Johnson & Johnson Services, Inc.
- 14.2.7. Allergan plc.
- 14.2.8. Depomed Inc.
- 14.2.9. Par pharmaceutical
- 14.2.10. Vertical pharmaceutical
- 15. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region
- 15.1. Introduction / Key Findings
- 15.2. Historical Market Size (US$ Mn) Analysis By Region, 2013–2017
- 15.2.1. North America
- 15.2.2. Western Europe
- 15.2.3. Eastern Europe
- 15.2.4. Latin America
- 15.2.5. Asia Pacific Excluding Japan
- 15.2.6. Japan
- 15.2.7. Middle East and Africa
- 15.3. Market Size (US$ Mn) Forecast By Region, 2018–2028
- 15.3.1. North America
- 15.3.2. Western Europe
- 15.3.3. Eastern Europe
- 15.3.4. Latin America
- 15.3.5. Asia Pacific Excluding Japan
- 15.3.6. Japan
- 15.3.7. Middle East and Africa
- 15.4. Key Trends / Developments
- 15.5. Market Attractiveness Analysis By Region
- 16. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
- 16.2.1. Anticonvulsant
- 16.2.2. Tricyclic Antidepressant
- 16.2.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 16.2.4. Hormone
- 16.2.5. Nerve Block
- 16.2.6. Local Anesthetic
- 16.2.7. Others
- 16.3. Market Size (US$ Mn) Forecast By Drug Class, 2018–2028
- 16.3.1. Anticonvulsant
- 16.3.2. Tricyclic Antidepressant
- 16.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
- 16.3.4. Hormone
- 16.3.5. Nerve Block
- 16.3.6. Local Anesthetic
- 16.3.7. Others
- 16.4. Market Attractiveness Analysis By Drug Class
- 17. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Mode Of Administration
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
- 17.2.1. Oral
- 17.2.2. Topical
- 17.2.3. Injectable
- 17.3. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
- 17.3.1. Oral
- 17.3.2. Topical
- 17.3.3. Injectable
- 17.4. Market Attractiveness Analysis By Mode Of Administration
- 18. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
- 18.2.1. Hospital Pharmacies
- 18.2.2. Retail Pharmacies
- 18.2.3. Drug Stores
- 18.2.4. Online Pharmacies
- 18.3. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
- 18.3.1. Hospital Pharmacies
- 18.3.2. Retail Pharmacies
- 18.3.3. Drug Stores
- 18.3.4. Online Pharmacies
- 18.4. Market Attractive Analysis By Distribution Channel